Literature DB >> 6602018

Decreased TCGF activity in the culture medium of PHA stimulated peripheral mononuclear cells from patients with metastatic cancer.

E Nakayama, S Asano, N Takuwa, J Yokota, S Miwa.   

Abstract

Activities of T cell growth factor (TCGF) of conditioned media from PHA stimulated cultures of peripheral mononuclear cells (PHA-MNC-CM) were compared among patients with cancer, patients with non-malignant disease and normal persons. In nine out of 10 cases of cancer with metastasis (including extensive infiltration to surrounding tissues), the activities were much lower than normal persons, whereas in four out of five cases of cancer without metastasis, the activities were almost the same as those of normal persons. The low activities of PHA-MNC-CM from patients with metastatic cancer were not due to the older age of patients, nor did it seem to be attributed to the malnutritional state of patients. When we examined the activity using non-adherent MNC instead of the whole MNC, the activities in patients with metastatic cancer rose up to almost the normal levels. In normal persons the decline of the activities after 3 days of culture were not observed after the removal of adherent cells. Our data indicate that the adherent cells have a suppressive effect on TCGF production in both normal persons and cancer patients, but that the effect may be exaggerated in patients with metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602018      PMCID: PMC1536770     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  Human T cell growth factor. I. Optimal conditions for its production.

Authors:  J M Alvarez; A Silva; M O de Landazuri
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

2.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

3.  Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells.

Authors:  M Zembala; B Mytar; T Popiela; G L Asherson
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

4.  Adherent cells (macrophages?) in tumor-bearing mice suppress MLC responses.

Authors:  H J Garrigues; P Romero; I Hellström; K E Hellström
Journal:  Cell Immunol       Date:  1981-05-01       Impact factor: 4.868

Review 5.  Depressed immunity and the development of cancer.

Authors:  I Penn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

6.  Colony formation by T-lymphocytes infiltrating human tumours.

Authors:  S Asano; M Goodyear; G F Burns; P F Bartlett; I R MacKay
Journal:  Immunol Lett       Date:  1981-04       Impact factor: 3.685

7.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

8.  TCGF production for cloning and growth of functional human T lymphocytes.

Authors:  H Inouye; J A Hank; B J Alter; F H Bach
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

9.  Colonies formed in agar from human breast cancer and their identification as T-lymphocytes.

Authors:  S Asano; T E Mandel
Journal:  J Natl Cancer Inst       Date:  1981-07       Impact factor: 13.506

10.  Regulation of T cell growth factor production: arrest of TCGF production after 18 hours in normal lectin-stimulated mouse spleen cell cultures.

Authors:  M Gullberg; F Ivars; A Coutinho; E L Larsson
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

View more
  7 in total

1.  Decreased interleukin generation in patients with cancer of the digestive system. A correlation between interleukin 1 and interleukin 2 production.

Authors:  Y Haga; K Sakamoto; Y Yokoyama; M Akagi
Journal:  Jpn J Surg       Date:  1988-09

2.  Impaired production of interleukin-2 after surgery.

Authors:  T Akiyoshi; F Koba; S Arinaga; S Miyazaki; T Wada; H Tsuji
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

3.  Interleukin 2 activity in chronic liver disease and the effect of in vitro alpha-interferon.

Authors:  S Saxena; K T Nouri-Aria; M G Anderson; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

4.  Immunodepression after surgery: impaired production of interleukin 2.

Authors:  T Akiyoshi; F Koba; S Miyazaki; S Arinaga; T Wada; H Tsuji
Journal:  Jpn J Surg       Date:  1984-09

5.  Interleukin 2 and interferon-gamma activities of mononuclear cells from regional lymph nodes in patients with gastric cancer.

Authors:  K Kusugami; T Matsuura; T Kawase; K Ina; H Matsunaga; Y Kuwahara; T Inagaki; K Morise; K Shimokata
Journal:  Gastroenterol Jpn       Date:  1990-06

6.  Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.

Authors:  P Lissoni; G Tancini; F Rovelli; G Cattaneo; C Archili; S Barni
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

7.  Interleukin-2 receptor and ovarian cancer.

Authors:  O J Owens; C Taggart; R Wilson; J J Walker; J H McKillop; J H Kennedy
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.